Read More Pharma Industry News Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted… byPallavi MadhirajuSeptember 20, 2024